CEO pay rebounds across ASX health and biotech as boards balance pressure and retention
Executive remuneration in Australia’s health care and biotechnology sectors rose modestly in the last financial year, with a 7.2 per cent increase in total CEO pay, according to the 2025…
Health Check: The latest ASX biotech IPO is out of the blocks
Nexsen is off and running on its great ASX marathon. Pic: Getty Images Diagnostic play Nexsen surges 47% on its ASX debut, after a well-supported raising Audeara has entered the…
Could Trump’s second act boost these ASX psychedelic stocks?
Speculation RFK Jr’s appointment to head US Department of Health and Human Services may favourably impact medical psychedelics sector Tryptamine’s lead asset TRP-8803 is an innovative and scalable psilocin-based IV-infusion…